Table of contents
In this issue
p245 | doi:10.1038/nrd1083
Editorial: Costing drug development
p247 | doi:10.1038/nrd1070
Research Highlights
Research funding: The ties that bind
p249 | doi:10.1038/nrd1071
Therapeutic proteins: Polymer-perfect proteins
p250 | doi:10.1038/nrd1074
Chemical genetics: Combichem leads for asthma
p250 | doi:10.1038/nrd1076
Anticoagulants: The clot thickens
p251 | doi:10.1038/nrd1078
Structure-based drug design: An ACE surprise
p252 | doi:10.1038/nrd1072
Neurodegenrative disease: Come on everybody, do the congo!
p252 | doi:10.1038/nrd1077
Lead discovery: Get a grip
p253 | doi:10.1038/nrd1075
In brief
Anticancer Drugs | Computational Chemistry | Stroke | Anticancer Drugs
p253 | doi:10.1038/nrd1079
Protein folding diseases: Raising the bar
p254 | doi:10.1038/nrd1073
News and Analysis
Patent watch
Gabbing about gabapentin | Pharmacia pilots patent share for HIV drug
p254 | doi:10.1038/nrd1080
From the analyst's couch
Biotech's fallen angels
p255 | doi:10.1038/nrd1069
Fresh from the Pipeline
Teriparatide
p257 | doi:10.1038/nrd1068
Reviews
Article series: A guide to drug discovery
A guide to drug discovery: Designing screens: how to make your hits a hit
W. Patrick Walters & Mark Namchuk
p259 | doi:10.1038/nrd1063
Targeting the CREB pathway for memory enhancers
Tim Tully, Rusiko Bourtchouladze, Rod Scott & John Tallman
p267 | doi:10.1038/nrd1061
Antiherpesvirus drugs: a promising spectrum of new drugs and drug targets
Donald M. Coen & Priscilla A. Schaffer
p278 | doi:10.1038/nrd1032
Challenges for the oral delivery of macromolecules
Michael Goldberg & Isabel Gomez-Orellana
p289 | doi:10.1038/nrd1067
Issues and progress with protein kinase inhibitors for cancer treatment
Janet Dancey & Edward A. Sausville
p296 | doi:10.1038/nrd1066
Perspectives
Timeline
Discovering risperidone: the LSD model of psychopathology
Francis C. Colpaert
p315 | doi:10.1038/nrd1062
Timeline
A brief history of novel drug discovery technologies
Leland J. Gershell & Joshua H. Atkins
p321 | doi:10.1038/nrd1064
